-
Sunitinib, sold
under the
brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted
receptor tyrosine kinase (RTK) inhibitor...
-
effectiveness of
everolimus in
carcinoid tumors have not been established.
sunitinib (Sutent) is
labeled for
treatment of progressive, well-differentiated...
- (NSCLC).
Sunitinib is an oral drug that
inhibits the
phosphorylation of all the VEGF receptors, PDGFR-ß, KIT FLT3, CSF1R and GDNF.
Sunitinib is used in...
-
cytokine therapy (IL-2, interferon),
kinase inhibitors (temsirolimus,
sunitinib, sorafenib, pazopanib) and anti-angiogenic
therapies (bevacizumab). "Clear...
-
randomized study of
zanzalintinib in
combination with
nivolumab versus sunitinib in
patients with
advanced or
metastatic non-clear cell RCC (nccRCC). Sharma...
- phosphate. It was
developed by
SUGEN as SU11654, a
sister compound to
sunitinib,
which was
later approved for
human therapies.
Toceranib is a tyrosine...
- shut down in 2003,
after developing the
pioneering kinase inhibitor drug
sunitinib (Sutent).
Sugen was
founded in 1991 in
Redwood City, California, by veteran...
- multiple-tyrosine-kinase
inhibitor sunitinib (marketed as Sutent) can be considered.: 26 and 31 The
effectiveness of
imatinib and
sunitinib depends on the genotype...
-
patients and as an anti-fatigue
agent in
kidney cancer patients treated with
sunitinib.
There is a
single case
report of its use in the
successful treatment...
-
small molecules that
inhibit the
tyrosine kinases stimulated by VEGF:
sunitinib, sorafenib, axitinib, and
pazopanib (some of
these therapies target VEGF...
